PHARMA TECHNOLOGY
0443.803.803 · rovalta.com · 08/11/2026
PHARMA TECHNOLOGY
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBOPHARMA TECHNOLOGY is a Public limited company incorporated in 1991. Its main activity is: Manufacture of other special-purpose machinery n.e.c.. Its registered office is in Nivelles. It employs on average 69,9 ETP workers (FTE).
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0443.803.803
- Incorporation
- 29/03/1991
- Legal form
- Public limited company
- Registered office
- Rue Graham Bell 8
1402 Nivelles · WallonieSee on map - Contributed capital
- 61 973,38 €
- Latest accounts
- 31/12/2025
- Average workforce
- 69,9 ETP
Joint committees (3)
- 111
- 209
- 218
Financials
Source · NBB, 21 filingsTrend over 20 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 26,8 M € | +1.2% | 26,5 M € | +7.7% | 24,6 M € | +25.2% | 19,6 M € | +1.2% | 19,4 M € |
| EBITDA | 5,7 M € | -6.8% | 6,1 M € | +7.8% | 5,6 M € | +43.5% | 3,9 M € | -14.4% | 4,6 M € |
| Operating result | 4,2 M € | -4.6% | 4,4 M € | +7.6% | 4,1 M € | +38.4% | 3 M € | -22.3% | 3,8 M € |
| Net result | 3,8 M € | -13.0% | 4,3 M € | +10.3% | 3,9 M € | +30.1% | 3 M € | -19.1% | 3,7 M € |
| Balance sheet | |||||||||
| Equity | 16,3 M € | +13.6% | 14,3 M € | +3.9% | 13,8 M € | -14.2% | 16,1 M € | -11.2% | 18,1 M € |
| Total assets | 23,9 M € | +1.6% | 23,5 M € | -8.4% | 25,7 M € | -1.3% | 26 M € | -0.2% | 26,1 M € |
| Cash | 2,1 M € | -60.7% | 5,4 M € | +114% | 2,5 M € | -12.2% | 2,9 M € | -56.3% | 6,6 M € |
| Debts | 7,4 M € | -16.3% | 8,8 M € | -24.2% | 11,7 M € | +22.2% | 9,5 M € | +25.7% | 7,6 M € |
| Other | |||||||||
| Workforce | 69,9 ETP | +5.7% | 66,1 ETP | -1.5% | 67,1 ETP | +11.6% | 60,1 ETP | -2.1% | 61,4 ETP |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20252 active · 1 ended
Active mandates
| Director | Mandates in this company | Period | Other mandatescurrentendedstruck offbankruptcies |
|---|---|---|---|
Claire Becker | Director01/04/2010 → 08/06/2028 | ||
| Managing director14/04/2008 → 08/06/2028 |
Ended mandates
| Director | Mandates in this company | Period | Other mandatescurrentendedstruck offbankruptcies |
|---|---|---|---|
Martial DOLLINGER | Managing director2009 accounts |
Other companies at this address
Rue Graham Bell 8 1402 Nivelles| Company | CBE no. |
|---|---|
AdFinitis● Active | 1012.280.815 |
DOLFINANCE● Active | 0444.022.844 |
DOLLIMMO BELGIUM● Active | 0765.300.009 |
NextGen Invest● Active | 1004.718.674 |
PHARMA FLEX● Active | 0897.187.147 |
PHARMA VAT UNIT● Active | 0654.817.207 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Full model | Full model | Full model | Full model | Full model | Full model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 27/03/2026 | 15/04/2025 | 19/06/2024 | 24/10/2023 | 27/07/2022 | 28/07/2021 |
| General meeting | 26/03/2026 | 26/03/2025 | 13/06/2024 | 08/06/2023 | 30/06/2022 | 24/06/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 21 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Full model | 31/12/2025 | 26/03/2026 | 27/03/2026 | French | |
| Full model | 31/12/2024 | 26/03/2025 | 15/04/2025 | French | |
| Full model | 31/12/2023 | 13/06/2024 | 19/06/2024 | French | |
| Full modelCorrection | 31/12/2022 | 08/06/2023 | 24/10/2023 | French | |
| Full model | 31/12/2022 | 08/06/2023 | 07/07/2023 | French | |
| Full model | 31/12/2021 | 30/06/2022 | 27/07/2022 | French | |
| Full model | 31/12/2020 | 24/06/2021 | 28/07/2021 | French | |
| Full model | 31/12/2019 | 29/06/2020 | 10/07/2020 | French | |
| Full model | 31/12/2018 | 13/06/2019 | 30/07/2019 | French | |
| Full model | 31/12/2017 | 14/06/2018 | 24/07/2018 | French | |
| Full model | 31/12/2016 | 08/06/2017 | 26/07/2017 | French | |
| Full model | 31/12/2015 | 09/06/2016 | 08/07/2016 | French | |
| Full model | 31/12/2014 | 11/06/2015 | 29/07/2015 | French | |
| Full model | 31/12/2013 | 12/06/2014 | 01/07/2014 | French | |
| Full model | 31/03/2013 | 20/09/2013 | 31/10/2013 | French | |
| Abridged model | 31/03/2012 | 21/09/2012 | 28/11/2012 | French | |
| Abridged model | 31/03/2011 | 16/09/2011 | 21/10/2011 | French | |
| Abridged model | 31/03/2010 | 17/09/2010 | 22/11/2010 | French | |
| Abridged model | 31/03/2009 | 18/09/2009 | 16/11/2009 | French | |
| Abridged model | 31/03/2008 | 19/09/2008 | 25/11/2008 | French | |
| Abridged model | 31/03/2007 | 21/09/2007 | 23/10/2007 | French |
Valuation
Indicative valuation
As an indication, this company is worth
between 25 M€ and 50 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20252 active · 1 ended
Active mandates
| Director | Mandates in this company | Period | Other mandatescurrentendedstruck offbankruptcies |
|---|---|---|---|
Claire Becker | Director01/04/2010 → 08/06/2028 | ||
| Managing director14/04/2008 → 08/06/2028 |
Ended mandates
| Director | Mandates in this company | Period | Other mandatescurrentendedstruck offbankruptcies |
|---|---|---|---|
Martial DOLLINGER | Managing director2009 accounts |
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Mandates24/01/2025DEMISSIONS, NOMINATIONS
- Other25/01/2024STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Mandates08/11/2022DEMISSIONS, NOMINATIONS
- Mandates03/10/2019DEMISSIONS, NOMINATIONS
- Registered office30/11/2017SIEGE SOCIAL
- Mandates05/09/2016DEMISSIONS, NOMINATIONS
- Mandates18/04/2016DEMISSIONS, NOMINATIONS
- Registered office06/10/2014SIEGE SOCIAL
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
Source · CBE, NBB annual accountsRegistered offices
Source · NBB annual accounts, CBE| Registered address | Period | Source |
|---|---|---|
| Rue Graham Bell 8, 1402 ThinesCurrent | accounts 2021 → 2025 | Accounts 2025 · 2026-00064296 |
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| PHARMA TECHNOLOGYCurrent | accounts 2021 → 2025 | Accounts 2025 · 2026-00064296 |
Events
- 2025Annual accounts 20253,8 M €↓
- 2024Annual accounts 20244,3 M €↑
- 2023Annual accounts 20233,9 M €↑
- 2022Annual accounts 20223 M €↓
- 2021Annual accounts 20213,7 M €↑
- 2020Annual accounts 20202,2 M €↓
- 2019Annual accounts 20193,3 M €↑
- 2018Annual accounts 20182,8 M €↑
- 2017Annual accounts 20171,4 M €↓
- 2016Annual accounts 20162,7 M €↑
- 2015Annual accounts 20152 M €↑
- 2014Annual accounts 20141,2 M €↑
- 2013Annual accounts 20131,1 M €↓
- 2013Annual accounts 20131,4 M €↑
- 2012Annual accounts 2012352,9 k €↑
- 2011Annual accounts 2011194,1 k €↓
- 2010Annual accounts 2010283,7 k €↑
- 2009Annual accounts 2009166,6 k €↓
- 2008Annual accounts 2008930,8 k €↓
- 2007Annual accounts 20071,2 M €
- 29/03/1991IncorporationPublic limited company